Truist initiated coverage of Tectonic Therapeutic (TECX) with a Buy rating and $64 price target Tectonic is advancing lead relaxin asset, TX45 for Group 2 pulmonary hypertension-heart failure with preserved ejection fraction and Truist is cautiously optimistic that TX45 will be successful in its ongoing Phase 2 study, the analyst tells investors in a research note. Truist likes the current risk-reward.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECX: